Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc covers the month of June 2022, specifically dated June 9, 2022. The report serves to disclose a corporate governance update regarding the appointment of a new non-executive director to the Company's board.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the expansion of the Board of Directors. On June 8, 2022, Siddharth (Sid) Kaul was appointed as a non-executive director. He was assigned to the Class II director category and joined both the Audit Committee and the Remuneration Committee effective on the same date.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The document focuses solely on the biographical background of the new appointee, noting his previous roles as Group Treasurer and CFO at Novartis International AG and his prior two-decade tenure at The Procter & Gamble Company. No risks, contingencies, or unusual items are discussed in this specific filing.
Key Facts for Investor Verification
- Verify the effective date of Siddharth Kaul's appointment (June 8, 2022) and his specific committee assignments (Audit and Remuneration).
- Confirm the classification of the new director as a Class II director.
- Review the attached Press Release (Exhibit 99.1) for any additional details on the appointment rationale not included in the summary text.
- Note that this filing does not update the Company's financial position or operational results.